ArticleThe Lancet regional health. Europe2025

Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.

Xingrong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.